Please upgrade your browser.
End-of-life-care expert Timothy Quill carries out a discussion with neurosurgeon Paul Kalanithi who was diagnosed in 2013 with advanced-stage lung cancer.
Treatment with an immune checkpoint inhibitor led to consistent responses across multiple types of cancer...
The number of cases of kidney cancer diagnosed each year in Great Britain has risen over 9,000 for the first time, new figures from Cancer Research UK show today.
Fargo, North Dakota, Mayor Dennis Walaker, the man known as the "flood mayor" for leading the state's largest city through several successful fights against the Red River, died Tuesday at his home.
Its lead drug, PV-10, is now part of the immunotherapy cancer treatment revolution
Most people with potential warning symptoms don’t have cancer, but some will and others may have other diseases that would benefit from early attention.
For the patient with advanced-stage kidney cancer, deciding on a course of treatment presents diverse choices...
High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pre-treated with VEGF-targeted agents, reveals research presented today at the ESMO Symposium on Immuno-Oncology in Geneva, Switzerland.
Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (nivolumab) and FPA008 in Six Tumor Typ
Bristol-Myers Squibb Company (NYSE:BMY) and Five Prime Therapeutics, Inc. (Nasdaq:FPRX) today announced that they have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibb’s investigational PD-1 (programmed death-1) immune checkpoint inhibitor, with FPA008, Five Prime’s monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R).
If you are a kidney cancer patient, 18 years of age or older, and you live in the NYC or Philadelphia area, we invite you to participate in this research. Interviews will take approximately 45 minutes and can be conducted at a location near your home between Dec 15 - 19, 2014.
|NeonCRM by Neon One|